XML 17 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Statement [Abstract]      
Revenues $ 589,462 $ 611,689 $ 143,167
Research and development expenses (Note 11) 3,207,466 2,881,817 2,268,345
Selling and Marketing (Note 12) 1,525,168 1,127,915 1,127,434
General and administrative expenses (Note 13) 6,432,679 2,257,799 1,402,741
Total operating expenses 11,165,313 6,267,531 4,798,520
Operating loss 10,575,851 5,655,842 4,655,353
Financing (income) expenses, net (Note 14) (247,045) (246,105) 1,186,819
Loss for the period (10,328,806) (5,409,737) (5,842,172)
Other comprehensive income (loss):      
Foreign currency translation adjustment 48,099 (27,592) 23,498
Comprehensive (loss) for the period $ (10,280,707) $ (5,437,329) $ (5,818,674)
Loss per share (Basic) (Note 16) $ (1.87) $ (1.08) $ (1.15)
Loss per share (Diluted) (Note 16) $ (1.87) $ (1.08) $ (1.15)
Common shares used in computing Basic Loss per share (Note 16) 6,285,324 5,788,842 5,476,870
Common shares used in computing Diluted Loss per share (Note 16) [1] 6,285,324 5,788,842 5,476,870
[1] In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2017, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series D Units. For December 31, 2016 and 2015, management estimation considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units and Series B Units (See Note 10C).